When the four drug classes—β-blockers, mineralocorticoid receptor antagonists, ARNIs, and SGLT2 inhibitors—are administered early and appropriately to HF patients, they can increase survival rate and reduce hospitalizations due to HF. Here, SLC5A2 is linked to hydrops fetalis.